BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 9272131)

  • 21. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
    Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
    Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
    De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
    Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. French APL Group.
    Fenaux P; Chastang C; Degos L
    Leukemia; 1994; 8 Suppl 2():S42-7. PubMed ID: 7815836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
    Miyawaki S; Tanimoto M; Kobayashi T; Minami S; Tamura J; Omoto E; Kuriyama K; Hatake K; Saito K; Kanamaru A; Oh H; Ohtake S; Asou N; Sakamaki H; Yamada O; Jinnai I; Tsubaki K; Takeyama K; Hiraoka A; Matsuda S; Takahashi M; Shimazaki C; Adachi K; Kageyama S; Ohno R
    Int J Hematol; 1999 Aug; 70(2):97-104. PubMed ID: 10497848
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy.
    de Botton S; Coiteux V; Chevret S; Rayon C; Vilmer E; Sanz M; de La Serna J; Philippe N; Baruchel A; Leverger G; Robert A; San Miguel J; Conde E; Sotto JJ; Bordessoule D; Fegueux N; Fey M; Parry A; Chomienne C; Degos L; Fenaux P
    J Clin Oncol; 2004 Apr; 22(8):1404-12. PubMed ID: 15084614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia.
    Cortes JE; Kantarjian H; O'Brien S; Robertson LE; Koller C; Hirsh-Ginsberg C; Stass S; Keating M; Estey E
    Cancer; 1994 Jun; 73(12):2946-52. PubMed ID: 8199992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy analysis of sequential treatment with chemotherapy, ATRA and As(2)O(3) for acute promyelocytic leukemia].
    Ma XJ; Ren HY; Cen XN; Qiu ZX; Wang WS; Ou JP; Wang Y; Xu WL; Li Y; Wang MJ; Wang LH; Dong YJ; Yin Y; Liang ZY
    Zhonghua Xue Ye Xue Za Zhi; 2010 May; 31(5):328-32. PubMed ID: 21122313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
    Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
    Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by all transretinoic acid (ATRA) combined with chemotherapy: The European experience. European APL Group.
    Fenaux P; Chastang C; Chomienne C; Castaigne S; Sanz M; Link H; Löwenberg B; Fey M; Archim-Baud E; Degos L
    Leuk Lymphoma; 1995 Feb; 16(5-6):431-7. PubMed ID: 7787753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
    Tallman MS; Andersen JW; Schiffer CA; Appelbaum FR; Feusner JH; Woods WG; Ogden A; Weinstein H; Shepherd L; Willman C; Bloomfield CD; Rowe JM; Wiernik PH
    Blood; 2002 Dec; 100(13):4298-302. PubMed ID: 12393590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Childhood acute promyelocytic leukemia: no benefit of all-trans-retinoic acid administered in a short-course schedule.
    Zubizarreta PA; Rose AB; Felice MS; Alfaro E; Delfino S; Cygler AM; Sackmann-Muriel F
    Pediatr Hematol Oncol; 2000 Mar; 17(2):155-62. PubMed ID: 10734658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of acute promyelocytic leukaemia using a combination of all-trans retinoic acid and chemotherapy.
    Koh LP; Goh YT; Teoh G; Tan P
    Ann Acad Med Singap; 2001 Jul; 30(4):401-8. PubMed ID: 11503549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine.
    Estey E; Thall PF; Pierce S; Kantarjian H; Keating M
    J Clin Oncol; 1997 Feb; 15(2):483-90. PubMed ID: 9053469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group.
    Fenaux P; Le Deley MC; Castaigne S; Archimbaud E; Chomienne C; Link H; Guerci A; Duarte M; Daniel MT; Bowen D
    Blood; 1993 Dec; 82(11):3241-9. PubMed ID: 8241496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Homoharringtonine in newly diagnosed acute promyelocytic leukemia treatment: a prospective, randomized controlled trial].
    Wang Y; Liu BC; Wei H; Lin D; Zhou CL; Liu KQ; Li W; Wei SN; Wang JY; Gong BF; Zhang GJ; Zhao XL; Liu YT; Gong XY; Li Y; Gu RX; Mi YC; Wang JX
    Zhonghua Xue Ye Xue Za Zhi; 2016 Mar; 37(3):183-8. PubMed ID: 27033753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Outcome of acute promyelocytic leukemia with homoharringtonine (HHT) and ATRA].
    Yuan Y; Li W; Lin D; Mi YC; Wang Y; Wei H; Liu BC; Zhou CL; Liu KQ; Wang JY; Wei SN; Gong BF; Zhao XL; Sun MY; Wan JX
    Zhonghua Xue Ye Xue Za Zhi; 2011 Nov; 32(11):752-7. PubMed ID: 22339911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined chemotherapy for acute promyelocytic leukemia: a meta-analysis.
    Li X; Wang C; Chen G; Ji B; Xu Y
    Hematology; 2017 Sep; 22(8):450-459. PubMed ID: 28480800
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.